Inovio Receives First FDA Approval for a DNA Medicine, Voceryq

Inovio Pharmaceuticals has received accelerated approval from the U.S. Food and Drug Administration (FDA) for Voceryq (INO-3107), making it the first FDA-approved DNA medicine in the U.S. Voceryq is intended to reduce the frequency of surgical interventions for adults with recurrent respiratory papillomatosis.